O	0	1	A
O	2	7	phase
O	8	10	II
O	11	21	randomized
O	22	27	study
O	28	37	comparing
B-intervention	38	47	navelbine
I-intervention	48	51	and
I-intervention	52	64	capecitabine
O	65	66	(
O	66	72	Navcap
O	72	73	)
O	74	82	followed
O	83	89	either
O	90	92	by
O	93	99	Navcap
O	100	102	or
O	103	105	by
O	106	112	weekly
B-control	113	122	docetaxel
O	123	125	in
O	126	129	the
O	130	135	first
O	135	136	-
O	136	140	line
O	141	150	treatment
O	151	153	of
O	154	157	HER
O	157	158	-
O	158	159	2
O	159	160	/
O	160	163	neu
O	164	172	negative
O	173	183	metastatic
O	184	190	breast
O	191	197	cancer
O	197	198	.

O	199	208	Following
O	209	212	the
O	213	219	proven
O	220	228	efficacy
O	229	232	and
O	233	245	tolerability
O	246	248	of
O	249	255	Navcap
O	256	259	and
O	260	266	Navcap
O	267	275	followed
O	276	278	by
O	279	288	docetaxel
O	289	291	in
O	292	295	the
O	296	305	treatment
O	306	308	of
O	309	312	MBC
O	312	313	,
O	314	315	a
O	316	321	phase
O	322	324	II
O	325	335	randomized
O	336	341	study
O	342	345	was
O	346	355	initiated
O	356	358	to
O	359	365	assess
O	366	369	the
O	370	373	ORR
O	374	376	of
O	377	381	both
O	382	386	arms
O	387	389	in
O	390	393	the
O	394	399	first
O	399	400	-
O	400	404	line
O	405	412	setting
O	413	415	of
O	416	419	MBC
O	419	420	.

B-eligibility	421	429	Patients
I-eligibility	430	434	with
I-eligibility	435	437	no
I-eligibility	438	443	prior
I-eligibility	444	456	chemotherapy
I-eligibility	457	460	for
I-eligibility	461	464	MBC
I-eligibility	465	468	and
I-eligibility	469	472	HER
I-eligibility	472	473	-
I-eligibility	473	474	2
I-eligibility	474	475	/
I-eligibility	475	478	neu
I-eligibility	479	487	negative
O	488	492	were
O	493	501	eligible
O	501	502	.

O	503	506	All
O	507	515	patients
O	516	524	received
O	525	531	Navcap
O	532	533	(
O	533	534	V
O	535	537	25
O	538	540	mg
O	540	541	/
O	541	543	m2
O	544	546	on
O	547	549	d1
O	550	553	and
O	554	556	d8
O	557	560	and
O	561	562	C
O	563	566	825
O	567	569	mg
O	569	570	/
O	570	572	m2
O	573	576	bid
O	577	579	D1
O	579	580	-
O	580	582	14
O	583	586	q3w
O	586	587	)
O	588	591	for
O	592	593	a
O	594	599	total
O	600	602	of
O	603	604	4
O	605	611	cycles
O	611	612	.

O	613	621	Patients
O	622	633	progressing
O	634	639	under
O	640	646	Navcap
O	647	651	were
O	652	661	withdrawn
O	662	665	and
O	666	674	received
O	675	684	docetaxel
O	685	687	as
O	688	694	second
O	694	695	-
O	695	699	line
O	700	709	treatment
O	709	710	.

O	711	719	Patients
O	720	730	responding
O	731	733	or
O	734	740	stable
O	741	745	were
O	746	756	randomized
O	757	759	to
O	760	761	2
O	762	766	arms
O	766	767	:
O	768	769	4
O	770	776	cycles
O	777	779	of
O	780	786	Navcap
O	787	788	(
O	788	789	A
O	789	790	)
O	791	793	or
O	794	796	12
O	797	803	weekly
O	804	813	docetaxel
O	814	815	(
O	815	817	25
O	818	820	mg
O	820	821	/
O	821	822	m
O	822	823	Â²
O	823	824	/
O	824	828	week
O	828	829	)
O	830	831	(
O	831	832	B
O	832	833	)
O	833	834	.

O	835	839	From
O	840	844	July
O	845	849	2004
O	850	852	to
O	853	857	July
O	858	862	2008
O	862	863	,
O	864	865	a
O	866	871	total
O	872	874	of
B-total-participants	875	878	106
O	879	887	patients
O	888	892	were
O	893	901	enrolled
O	901	902	.

B-total-participants	903	909	Ninety
I-total-participants	909	910	-
I-total-participants	910	914	four
O	915	923	patients
O	924	928	were
O	929	938	evaluable
O	939	945	before
O	946	959	randomization
O	959	960	,
O	961	965	with
O	966	967	a
O	968	976	clinical
O	977	984	benefit
O	985	987	of
O	988	990	58
O	990	991	%
O	991	992	.

O	993	999	Twenty
O	999	1000	-
O	1000	1003	one
O	1004	1012	patients
O	1013	1014	(
O	1014	1016	22
O	1016	1017	%
O	1017	1018	)
O	1019	1022	had
O	1023	1030	disease
O	1031	1042	progression
O	1043	1046	and
O	1047	1051	were
O	1052	1061	therefore
O	1062	1065	not
O	1066	1076	randomized
O	1076	1077	.

B-intervention-participants	1078	1083	Forty
I-intervention-participants	1083	1084	-
I-intervention-participants	1084	1087	one
O	1088	1096	patients
O	1097	1101	were
O	1102	1112	randomized
O	1113	1115	to
O	1116	1119	arm
O	1120	1121	A
O	1122	1125	and
B-control-participants	1126	1128	29
O	1129	1137	patients
O	1138	1140	to
O	1141	1144	arm
O	1145	1146	B
O	1146	1147	.

B-outcome	1148	1152	ORRs
O	1153	1157	were
B-iv-bin-percent	1158	1160	56
O	1161	1164	and
B-cv-bin-percent	1165	1167	71
I-cv-bin-percent	1167	1168	%
O	1169	1171	in
O	1172	1176	arms
O	1177	1178	A
O	1179	1182	and
O	1183	1184	B
O	1184	1185	,
O	1186	1198	respectively
O	1198	1199	.

O	1200	1203	The
B-outcome	1204	1210	median
I-outcome	1211	1215	time
I-outcome	1216	1218	to
I-outcome	1219	1230	progression
O	1231	1234	and
B-outcome	1235	1242	overall
I-outcome	1243	1251	survival
O	1252	1256	were
B-iv-cont-median	1257	1259	10
O	1260	1263	and
B-iv-cont-median	1264	1266	35
I-iv-cont-median	1267	1273	months
O	1274	1276	in
O	1277	1280	arm
O	1281	1282	A
O	1283	1286	and
B-cv-cont-median	1287	1289	12
O	1290	1293	and
B-cv-cont-median	1294	1296	37
I-cv-cont-median	1297	1303	months
O	1304	1306	in
O	1307	1310	arm
O	1311	1312	B
O	1312	1313	.

O	1314	1321	Adverse
O	1322	1328	events
O	1329	1333	were
O	1334	1338	mild
O	1338	1339	.

O	1340	1343	Arm
O	1344	1345	A
O	1345	1346	:
B-outcome	1347	1352	grade
I-outcome	1353	1354	3
I-outcome	1354	1355	-
I-outcome	1355	1356	4
I-outcome	1357	1368	neutropenia
O	1369	1370	(
B-iv-bin-percent	1370	1372	10
I-iv-bin-percent	1372	1373	%
O	1373	1374	)
O	1374	1375	,
B-outcome	1376	1381	grade
I-outcome	1382	1383	3
I-outcome	1384	1390	anemia
O	1391	1392	(
B-iv-bin-percent	1392	1393	5
I-iv-bin-percent	1393	1394	%
O	1394	1395	)
O	1395	1396	.

O	1397	1400	Arm
O	1401	1402	B
O	1402	1403	:
B-outcome	1404	1409	grade
I-outcome	1410	1411	3
I-outcome	1412	1423	neutropenia
O	1424	1425	(
B-cv-bin-percent	1425	1426	6
I-cv-bin-percent	1426	1427	%
O	1427	1428	)
O	1428	1429	,
B-outcome	1430	1435	grade
I-outcome	1436	1437	3
I-outcome	1438	1444	anemia
O	1445	1446	(
B-cv-bin-percent	1446	1447	6
I-cv-bin-percent	1447	1448	.
I-cv-bin-percent	1448	1449	2
I-cv-bin-percent	1449	1450	%
O	1450	1451	)
O	1451	1452	,
O	1453	1456	and
B-outcome	1457	1462	grade
I-outcome	1463	1464	2
I-outcome	1465	1473	alopecia
O	1474	1475	(
B-cv-bin-percent	1475	1477	12
I-cv-bin-percent	1477	1478	%
O	1478	1479	)
O	1479	1480	.

O	1481	1485	Both
O	1486	1492	Navcap
O	1493	1496	and
O	1497	1503	Navcap
O	1504	1512	followed
O	1513	1515	by
O	1516	1525	Docetaxel
O	1526	1534	regimens
B-outcome	1535	1539	were
I-outcome	1540	1549	tolerated
O	1550	1554	with
O	1555	1565	manageable
O	1566	1574	toxicity
O	1574	1575	,
O	1576	1584	offering
O	1585	1595	consistent
O	1596	1606	activities
O	1607	1609	in
O	1610	1615	terms
O	1616	1618	of
O	1619	1627	response
O	1628	1632	rate
O	1633	1636	for
O	1637	1647	metastatic
O	1648	1654	breast
O	1655	1661	cancer
O	1662	1670	patients
O	1670	1671	.
